Jonah McIntyre, MD
Family Practice · Atmore, ALNPI 1699752303
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 100 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 14.1% — the pattern of someone who eats at a lot of different presentations. Among family practice clinicians in AL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 100 payments — averaging $16.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$236
- Novo Nordisk$230
- Otsuka America Pharmaceutical, Inc.$122
- AstraZeneca$121
- Silk Road Medical, Inc.$111
- Merck$97
- plus $753 from 24 others
What the payments were for
- Food & beverage$1,669100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 13 | $236 |
| Novo Nordisk | 28 | $230 |
| Otsuka America Pharmaceutical, Inc. | 7 | $122 |
| AstraZeneca | 7 | $121 |
| Silk Road Medical, Inc. | 1 | $111 |
| Merck | 5 | $97 |
| Pfizer | 5 | $83 |
| Johnson & Johnson | 4 | $71 |
| Bayer | 3 | $66 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $55 |
| Novartis | 2 | $41 |
| Harmony Biosciences LLC | 1 | $39 |
| Avanir Pharmaceuticals, Inc. | 2 | $38 |
| Biogen | 1 | $32 |
| Atland Pharmaceuticals, LLC | 1 | $31 |
| Dexcom, Inc. | 2 | $31 |
| Lilly USA, LLC | 2 | $30 |
| Abbott | 1 | $27 |
| Xeris Pharmaceuticals, Inc. | 1 | $24 |
| Neurocrine Biosciences, Inc. | 1 | $22 |
| Ardelyx, Inc. | 1 | $21 |
| Amgen | 1 | $19 |
| Shield Therapeutics Inc | 1 | $18 |
| Sumitomo Pharma America, Inc. | 1 | $18 |
| Hologic Inc | 1 | $15 |
| Esperion Therapeutics, Inc. | 1 | $15 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Boehringer Ingelheim | 1 | $14 |
| Paratek Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,669 in reported general payments places this provider in the 90th percentile of 71 family practice providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 202 | $226,686 |
| EliquisApixaban | 309 | $161,814 |
| IngrezzaValbenazine Tosylate | 24 | $88,685 |
| Tresiba Flextouch U-200Insulin Degludec | 38 | $77,365 |
| JardianceEmpagliflozin | 77 | $76,352 |
| LinzessLinaclotide | 98 | $67,388 |
| NuplazidPimavanserin Tartrate | 28 | $66,739 |
| TrulicityDulaglutide | 52 | $61,008 |
| MounjaroTirzepatide | 38 | $48,252 |
| JanuviaSitagliptin Phosphate | 71 | $46,755 |
| FarxigaDapagliflozin Propanediol | 52 | $44,167 |
| MyrbetriqMirabegron | 64 | $43,268 |
| EntrestoSacubitril/Valsartan | 34 | $35,393 |
| XareltoRivaroxaban | 42 | $32,984 |
| XifaxanRifaximin | 11 | $32,130 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $230 | $226,686202 claims |
| PfizerEliquis | $83 | $161,814309 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $30 | $109,25990 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat, Spiriva Respimat | $14 | $103,709117 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $22 | $88,68524 claims |
| AbbVieLinzess, Qulipta | $236 | $81,264110 claims |
| MerckJanuvia | $97 | $46,75571 claims |
| AstraZenecaFarxiga | $121 | $44,16752 claims |
| NovartisEntresto | $41 | $35,39334 claims |
| Johnson & JohnsonXarelto | $71 | $32,98442 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $55 | $32,13011 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $122 | $16,66120 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 71 family practice providers in Alabama.
Other family practice in Atmore
- Douglas GinasAlbertville$6K
- Stephen WinstonFairhope$5K
- Embril EdwardsGuntersville$4K
- Christopher JohnsonHuntsville$3K
- Adam AltermanRainbow City$545
- Katherine VintsonCullman$420
- Julia ToddHuntsville$150
- Rebecca ConwayHuntsville$118
- Jesse AustinMontgomery$53
- Laura SatcherHuntsville$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.